Background: Transarterial radioembolization (TARE) is used to treat primary and secondary malignancies in the liver that are not amenable to curative resection. Accumulating evidence demonstrates the efficacy and safety of TARE with yttrium-90 (90Y), which is the most widely used radionuclide for TARE, and later with holmium-166 (166Ho) for various indications. However, the safety and efficacy of166Ho TARE in patients with intrahepatic cholangiocarcinoma (ICC) remains to be studied. Methods: This was a retrospective case series study of seven consecutive patients with ICC who were treated with166-Ho-TARE in our center. We recorded the clinical parameters and outcomes of the TARE procedures, the tumor response according to mRECIST, subsequent treatments, and adverse events. Results: Three out of the seven patients had a partial or complete response. Two patients had stable disease after the first TARE procedure, and two of the patients (one with a complete response, and one with stable disease) were alive at the time of analysis. No serious adverse events related to the procedure were recorded. Conclusions: This is the first case series reporting the safety and tumor response outcomes of166Ho-TARE for ICC. The treatment demonstrated its versatility, allowing for reaching a high tumor dose, which is important for improving tumor response and treating patients in a palliative setting, where safety and the preservation of quality of life are paramount.
背景：经动脉放射栓塞术（TARE）用于治疗无法根治性切除的肝脏原发性和继发性恶性肿瘤。越来越多的证据表明，使用钇-90（90Y）进行TARE的疗效和安全性良好，90Y是目前TARE最广泛使用的放射性核素，随后钬-166（166Ho）也应用于多种适应症。然而，166Ho TARE在肝内胆管癌（ICC）患者中的安全性和有效性仍有待研究。方法：本研究为回顾性病例系列研究，纳入了在我中心连续接受166Ho-TARE治疗的7例ICC患者。我们记录了TARE手术的临床参数和结果、根据mRECIST标准评估的肿瘤反应、后续治疗以及不良事件。结果：7例患者中有3例达到部分或完全缓解。2例患者在首次TARE后疾病稳定，其中2例（1例完全缓解，1例疾病稳定）在分析时仍存活。未记录到与手术相关的严重不良事件。结论：这是首个报告166Ho-TARE治疗ICC安全性和肿瘤反应结果的病例系列研究。该治疗展现了其多功能性，能够实现较高的肿瘤剂量，这对于改善肿瘤反应以及在姑息治疗中至关重要，其中安全性和生活质量的维持至关重要。
肿瘤(癌症)患者之家